How Cost, Access, And Awareness Barriers Are Slowing Brca Testing

Despite broader guidelines and life-saving targeted therapies, real-world grounds reveals persistent gaps and inequities successful BRCA testing, raising urgent questions astir who gets entree to precision crab attraction and why. 

Study: BRCA testing patterns successful bosom crab complete clip successful nan United States: challenges and opportunities for improvement. Image credit: Olena Yakobchuk/Shutterstock.com

A recent Frontiers successful Oncology study summarizes real-world patterns of BRCA testing among bosom crab patients successful nan U.S., identifies misconceptions and barriers to testing uptake, and highlights areas requiring further investigation and intervention.

Genetic consequence factors and testing approaches successful bosom cancer

BRCA1 and BRCA2 are genes that play a important domiciled successful repairing damaged DNA wrong cells. When mutations hap successful these genes, nan repair process is disrupted, expanding nan consequence that cells will create into cancer. Mutations successful BRCA1 and BRCA2 tin beryllium inherited from a genitor (germline, gBRCAm). Individuals pinch inherited BRCA1 aliases BRCA2 mutations look a substantially higher life consequence of processing bosom crab compared to nan wide population. Understanding nan domiciled of these cistron mutations is basal for assessing bosom crab consequence and guiding objective decisions.

gBRCAm are linked to earlier bosom crab onset, fierce tumor characteristics, and triple-negative bosom crab (TNBC), which has poorer outcomes than different subtypes. BRCA1 mutations often lead to TNBC, while BRCA2 mutations are much commonly associated pinch hormone receptor-positive (HR+)/human epidermal maturation facet receptor 2 (HER2)-negative disease. Despite nan relation pinch early diagnosis, galore US patients pinch gBRCAm bosom crab are complete 50 and person HR+/HER2-negative disease, highlighting nan request for amended recognition successful this group.

Genetic testing for high-risk bosom crab genes, including gBRCAm, has been recommended for patients diagnosed astatine property 50 aliases younger, aliases astatine immoderate property pinch further consequence factors specified arsenic family history, tumor features, aliases ancestry. Guidelines person expanded successful caller years, pinch ASCO-SSO recommending testing for each patients diagnosed astatine property 65 aliases younger, and for older patients pinch consequence factors. NCCN guidance is much nuanced and recommends testing aliases information based connected property and objective characteristics to amended discovery and management.

While broader testing criteria and little costs person accrued access, galore eligible individuals stay untested, and real-world uptake of familial testing continues to lag contempt its benefits for prevention and personalized care.

Review rationale and lit synthesis

To amended understand barriers to familial testing for bosom cancer, researchers conducted a targeted lit reappraisal to synthesize grounds connected existent testing patterns and challenges to broader implementation successful nan US. Relevant articles were identified from Embase, MEDLINE, MEDLINE In Progress, and PsycINFO via OvidSP®, utilizing some free-text and MeSH terms.

The existent reappraisal included US-based real-world studies involving patients pinch bosom crab eligible for BRCA testing and healthcare professionals participating successful BRCA testing decisions. Studies focusing connected individuals eligible for BRCA testing but not diagnosed pinch bosom cancer were excluded.

Eligible studies reported connected testing patterns, including nan proportionality of patients who received aliases declined BRCA testing, nan timing of testing, and misconceptions aliases barriers to BRCA testing for curen decisions. To guarantee nan inclusion of caller and robust evidence, studies published earlier 2014 aliases pinch less than 450 patients were excluded.

Studies were screened successful 2 stages: titles and abstracts, followed by full-text review, applying PICOS criteria (population, intervention, comparison, outcomes, study design).

Real-world trends and determinants of BRCA testing uptake successful bosom cancer

Of 2,003 records screened, 35 publications, representing 32 unsocial studies, met eligibility; 28 focused connected real-world BRCA testing patterns, 7 unsocial studies (reported successful 9 publications) examined beliefs and attitudes, and 11 unsocial studies (reported successful 13 publications) identified barriers to testing among patients, HCPs, and payers.

BRCA testing rates for bosom crab ranged from 14 % to 87 % and accrued complete time. Study periods, diligent criteria, and reporting methods varied. Routine ordering of BRCA testing by providers appeared to summation based connected study comparisons betwixt 2018 and 2023.

BRCA testing rates differed by bosom crab subtype. Higher testing rates were seen successful patients pinch TNBC compared to those pinch HR+/HER2-negative bosom crab successful precocious aliases metastatic cases. In contrast, for early bosom cancer, testing rates for TNBC were sometimes little than for HR+/HER2-negative cases. Over time, testing rates for HR+/HER2-negative early bosom crab accrued significantly.

BRCA testing was astir communal among high-risk patients, particularly arsenic eligibility criteria broadened. Testing rates were higher for earlier-stage disease, younger age, backstage insurance, and successful world aliases larger practices. In contrast, it was little among Black patients, those successful smaller practices, aliases pinch providers who spot less patients aliases person less years successful practice.

Surgeons astir often ordered BRCA testing, pinch aesculapian oncologists and familial counselors besides involved. Surgeon assurance successful familial counseling grew pinch experience. In world centers, familial counselors much often ordered tests. Some grounds suggested that entree to familial counseling did not ever alteration ordering frequency, though different findings bespeak it tin amended referrals and uptake, highlighting mixed effects.

Among surgically treated early bosom crab patients, 14–78 % received BRCA testing pre-surgery. Earlier testing was much communal among younger, much educated, shape II aliases TNBC patients, and those progressive successful surgical decisions. Most testing occurred wrong 3 months of diagnosis, pinch rates rising complete time.

Negative attitudes and disbelief successful nan benefits of BRCA testing reduced testing, while affirmative attitudes accrued it. Cost was a predominant barrier, and Black patients reported much antagonistic attitudes than White patients. Patients sought testing for curen and family benefit, but faced barriers including cost, intelligence health, security fears, family impact, and deficiency of knowledge. Some patients reported that clinicians discouraged testing based connected perceived risk, subtype, security status, aliases ethnicity, contempt guidelines that do not restrict testing by title aliases ethnicity.

HCPs faced logistical and costs barriers, and payer controls specified arsenic anterior authorization reduced information to test. Providers unfastened to invention aliases pinch entree to counseling ordered much tests, while those serving much uninsured patients ordered fewer.

Key drivers for accrued BRCA testing included updated guidelines, little costs, collaboration pinch familial counselors, and greater diligent awareness. Persistent barriers included reimbursement challenges, constricted knowledge sharing, a deficiency of counseling resources, diligent concerns, and slow turnaround. Payers cited overutilization successful low-risk patients, incomplete documentation, unclear guidelines, constricted inferior for curen selection, and insufficient expertise arsenic barriers.

Limitations and early opportunities

BRCA testing rates successful bosom crab person risen, yet important disparities and barriers persist. This reappraisal highlights grounds gaps, including outdated data: astir included studies person information postulation periods earlier 2020, constricted investigation connected multigene sheet and cascade testing, and scarce payer perspectives, each compounded by varied study designs. To guarantee existent practices are reflected, early studies should reside these limitations and analyse nan effect of evolving guidelines and caller therapies, including nan domiciled of PARP inhibitors specified arsenic olaparib successful shaping testing uptake.

Improving BRCA testing uptake will require targeted acquisition for providers, payers, and patients, particularly successful organization settings and among Black patients. Innovative attraction models, specified arsenic telehealth, greater entree to familial counseling, and clearer accusation connected costs and coverage, could heighten BRCA testing. Addressing these challenges is important for equitable and timely BRCA testing, yet improving diligent outcomes.

Download your PDF transcript by clicking here.

The study was funded by Merck Sharp & Dohme LLC and AstraZeneca, companies progressive successful processing BRCA-targeted therapies, pinch funder labor participating successful study design, information interpretation, and manuscript preparation.